The purpose of this research was to test whether one treatment was superior over another in
the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody
positive type 2 diabetic patients to determine whether treatment with rosiglitazone results
in greater preservation of beta cell function compared to treatment with glyburide.
Phase:
N/A
Details
Lead Sponsor:
University of Washington
Collaborators:
GlaxoSmithKline Seattle Institute for Biomedical and Clinical Research